1. reported anamnesis for: 1. intolerance or previous toxicity for hydroxychloroquine/chloroquine 2. bradycardia or reduction rhythm of heart with arrythmias 3. ischemic heart disease 4. retinopathy 5. congestive heart failure under/with use of diuretics 6. favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. diabetes type 1 8. major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. 9. severe neurological and mental illness 2. any other contraindication to take hydroxychloroquine 3. already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks 4. use of other antiviral agents in the last 3 weeks 5. subject with a positive test for sars-cov-2 (for group 1) 6. pregnant or lactating 7. current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 8. known prolonged qt syndrome or current use of drugs with known qt prolongation 9. participation in another clinical trial with any investigational agents within 30 days prior to study screening.

1. reported anamnesis for: 1. intolerance or previous toxicity for hydroxychloroquine/chloroquine 2. bradycardia or reduction rhythm of heart with arrythmias 3. ischemic heart disease 4. retinopathy 5. congestive heart failure under/with use of diuretics 6. favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. diabetes type 1 8. major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. 9. severe neurological and mental illness 2. any other contraindication to take hydroxychloroquine 3. already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks 4. use of other antiviral agents in the last 3 weeks 5. subject with a positive test for sars-cov-2 (for group 1) 6. pregnant or lactating 7. current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 8. known prolonged qt syndrome or current use of drugs with known qt prolongation 9. participation in another clinical trial with any investigational agents within 30 days prior to study screening.

reported anamnesis for: intolerance or previous toxicity for hydroxychloroquine/chloroquine bradycardia or reduction rhythm of heart with arrythmias ischemic heart disease retinopathy congestive heart failure under/with use of diuretics favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency diabetes type 1 major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. severe neurological and mental illness any other contraindication to take hydroxychloroquine already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks use of other antiviral agents in the last 3 weeks subject with a positive test for sars-cov-2 (for group 1) pregnant or lactating current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 known prolonged qt syndrome or current use of drugs with known qt prolongation participation in another clinical trial with any investigational agents within 30 days prior to study screening.

reported anamnesis for: intolerance or previous toxicity for hydroxychloroquine/chloroquine bradycardia or reduction rhythm of heart with arrythmias ischemic heart disease retinopathy congestive heart failure under/with use of diuretics favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency diabetes type 1 major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. severe neurological and mental illness any other contraindication to take hydroxychloroquine already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks use of other antiviral agents in the last 3 weeks subject with a positive test for sars-cov-2 (for group 1) pregnant or lactating current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 known prolonged qt syndrome or current use of drugs with known qt prolongation participation in another clinical trial with any investigational agents within 30 days prior to study screening.

1. reported anamnesis for: 1. intolerance or previous toxicity for hydroxychloroquine/chloroquine 2. bradycardia or reduction rhythm of heart with arrythmias 3. ischemic heart disease 4. retinopathy 5. congestive heart failure under/with use of diuretics 6. favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. diabetes type 1 8. major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. 9. severe neurological and mental illness 2. any other contraindication to take hydroxychloroquine 3. already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks 4. use of other antiviral agents in the last 3 weeks 5. subject with a positive test for sars-cov-2 (for group 1) 6. pregnant or lactating 7. current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 8. known prolonged qt syndrome or current use of drugs with known qt prolongation 9. participation in another clinical trial with any investigational agents within 30 days prior to study screening.

1. reported anamnesis for: 1. intolerance or previous toxicity for hydroxychloroquine/chloroquine 2. bradycardia or reduction rhythm of heart with arrythmias 3. ischemic heart disease 4. retinopathy 5. congestive heart failure under/with use of diuretics 6. favism or glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. diabetes type 1 8. major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy. 9. severe neurological and mental illness 2. any other contraindication to take hydroxychloroquine 3. already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks 4. use of other antiviral agents in the last 3 weeks 5. subject with a positive test for sars-cov-2 (for group 1) 6. pregnant or lactating 7. current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, cyclosporine, phenylbutazone, drugs that inhibit cyp2d6 8. known prolonged qt syndrome or current use of drugs with known qt prolongation 9. participation in another clinical trial with any investigational agents within 30 days prior to study screening.